Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Barcelona – page 208

3 147 clinical trials in Barcelona, Spain across 23 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Barcelona at a glance
3 147
clinical trials
  • Research sites23
Type of trial
Recruitment status
Quick filters

3 147 trials in Barcelona

Open in trial search

Graft versus host disease

Not recruiting

Study on the Safety and Effectiveness of Human Alpha1-Proteinase Inhibitor for Preventing Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplant.

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Human Alpha1-Proteinase Inhibitor
  • Sponsor:CSL Behring LLC

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Acute myeloid leukaemia

Not recruiting

Study of Gilteritinib and Chemotherapy for Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Astellas Pharma Global Development Inc.

Metastases to central nervous system+1

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Squamous cell carcinoma of skin

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Cervix carcinoma

Not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab for Patients With High-Risk, Locally Advanced Cervical Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Nivolumab and Ipilimumab with Chemotherapy for Patients with Stage IV Non-Small Cell Lung Cancer and Brain Metastases

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Fundacion GECP

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Pancreatic carcinoma metastatic

Not recruiting

Study on TTX-030, Budigalimab, and Chemotherapy for Untreated Metastatic Pancreatic Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:Trishula Therapeutics Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Barcelona

What the registry says about research in the country

01 Neurodegenerative Research

Innovative studies focusing on Alzheimer's Disease and Frontotemporal Dementia, utilizing advanced brain imaging techniques to track disease progression and evaluate new therapeutic approaches.

  • Cerebral tau aggregates assessment
  • Amyloid deposition tracking
  • Progressive supranuclear palsy research

Advanced neuroimaging studies using PET tracers to understand disease mechanisms.

02 Infectious Disease Prevention

Comprehensive vaccine trials targeting various infections including Respiratory Syncytial Virus, Cytomegalovirus, and Herpes Zoster.

  • RSV vaccine development for older adults
  • CMV prevention studies
  • COVID-19 booster research

Focus on developing effective immunization strategies for vulnerable populations.

03 Metabolic and Chronic Conditions

Research examining treatments for Type 1 Diabetes and obesity, alongside studies in bladder cancer and urinary tract infections.

  • Diabetes management therapies
  • Cancer immunotherapy trials
  • UTI vaccine development

Innovative approaches to chronic disease management and prevention.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.